logo/base Created with Sketch.

AASLD Practice Guidance
- Update 2023 -

On the clinical assessment and management of nonalcoholic fatty liver disease


Recommendations related to FibroScan®

The growing prevalence of fatty liver disease has led the American Association for the Study of Liver Diseases (AASLD) to call for expanded use of noninvasive liver evaluations.

The new Practice Guidance from the AASLD suggests the use of VCTE™, a patented technology used by FibroScan® solutions from Echosens, for detecting and diagnosing NAFLD in high-risk individuals, including those with type 2 diabetes (T2D).

Notable takeaways, as outlined in the Practice Guidance

• High-risk individuals, such as those with T2DM, medically complicated obesity,
family history of cirrhosis, or more than mild alcohol consumption,
should be screened for advanced fibrosis.

• If FIB-4 result is >1.3, VCTE™ (FibroScan®)
may be used to exclude advanced fibrosis.

• CAP™ (FibroScan®) as a point-of-care technique
that may be used to identify steatosis.

• VCTE™ (FibroScan®) is the most commonly used method
to asses liver stiffness and can be used to exclude significant hepatic fibrosis.